Umedeor
Anil S Jina, MD, serves as the Chief Medical Officer (fractional) at Prudentia Sciences since July 2023 and holds dual roles as Chief Medical Officer and President at uMed since April 2023, where the focus is on enabling a global network for clinical and real-world research. As an Executive in Residence at Iaso Ventures since December 2022, Anil S Jina drives innovation in neuroscience startups. Previously, Anil S Jina was Chief Medical Officer at Akili Interactive, leading the FDA clearance of a therapeutic video game and participating in significant financial ventures. Anil S Jina has also held senior roles at PPD and Axcella, and served as Chief Medical Officer at Evelo Biosciences and Shire. Anil S Jina's career includes extensive leadership in medical affairs and drug development at Sanofi and Pfizer. Anil S Jina earned an MB BCh BAO in Medicine from the Royal College of Surgeons in Ireland.
This person is not in any teams
This person is not in any offices
Umedeor
uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries. This enables sites to participate in dozens of programmes simultaneously without increasing overhead or burden on staff. For life science companies, uMed provides access toregulator quality data, where patients within those datasets can be compliantly re-engaged to support the aims of R&D and post-market teams